Healthcare Stocks Ending Higher; Myriad Genetics Back Near Day's High On Strong Results for Melanoma Test
Top Healthcare Stocks
Healthcare stocks are mostly higher this afternoon with the NYSE Healthcare Sector Index adding 0.5% and shares of healthcare companies in the S&P 500 advancing just over 0.6% as a group.
In company news, Myriad Genetics, Inc. ( MYGN ) is up 5% to $23.90, retracing its path to an intra-day high of $23.98 and the molecular diagnostic company saying results from a verification study showed its myPath Melanoma test effectively differentiated malignant melanoma from benign skin lesions.
The verification study evaluated a 23-gene panel designed to differentiate malignant melanoma from benign skin lesions. The myPath Melanoma test demonstrated high sensitivity of 89% and specificity of 93% at differentiating malignant melanoma from benign skin lesions.
In other sector news,
(+) ATRS, The company's Otrexup injection for rheumatoid arthritis was approved by the U.S. Food and Drug Administration.
(-) CNDO, Said its TSO drug candidate to treat Crohn's disease failed to meet its primary endpoints during Phase II testing.